Medicine and Dentistry
Wet Macular Degeneration
82%
Diabetic Macular Edema
81%
Diabetic Retinopathy
77%
Aflibercept
73%
Age Related Macular Degeneration
72%
Vasculotropin
65%
Visual Acuity
58%
Best Corrected Visual Acuity
49%
Ranibizumab
48%
Optical Coherence Tomography
40%
Retinal Detachment
39%
Meta-Analysis
33%
Fluorescein Angiography
31%
Brolucizumab
31%
Geographic Atrophy
30%
Proliferative Diabetic Retinopathy
29%
Macular Hole
27%
Retina Vein Occlusion
26%
Clinical Trial
25%
Randomized Clinical Trial
24%
Laser Coagulation
22%
Diseases
21%
Intravitreal Administration
20%
Pars Plana Vitrectomy
20%
Systematic Review
20%
Biological Marker
18%
Post-Hoc Analysis
18%
Ophthalmology
15%
COVID-19
15%
Macular Degeneration
15%
Macular Edema
14%
Hypoxia
13%
Adverse Event
13%
Endothelial Cell Growth Factor
13%
Endophthalmitis
12%
Pegcetacoplan
12%
Faricimab
12%
Arm
12%
Visual Impairment
11%
Scleral Buckle
11%
Agents Acting on the Eye
10%
Vitrectomy
10%
Randomized Controlled Trial
10%
Carbonate Dehydratase IX
10%
Retinal Vasculitis
9%
Neoplasm
9%
Disease Activity
9%
Retreatment
9%
Avacincaptad Pegol
9%
Retina Blood Vessel Occlusion
8%
Pharmacology, Toxicology and Pharmaceutical Science
Diabetic Macular Edema
100%
Aflibercept
92%
Wet Macular Degeneration
78%
Ranibizumab
67%
Diabetic Retinopathy
52%
Vasculotropin
52%
Age Related Macular Degeneration
32%
Proliferative Diabetic Retinopathy
32%
Randomized Clinical Trial
31%
Clinical Trial
29%
Faricimab
27%
Adverse Event
20%
Brolucizumab
18%
Endothelial Cell Growth Factor
18%
Diseases
17%
Fluorescein
16%
Retina Vein Occlusion
16%
Intravitreal Administration
14%
Inflammation
13%
Visual Impairment
12%
Retina Detachment
11%
Fluocinolone Acetonide
10%
Randomized Controlled Trial
10%
Macular Edema
9%
Combination Therapy
9%
Geographic Atrophy
9%
Disease Activity
9%
Uveitis
9%
Pharmacokinetic
8%
Retina Disease
8%
Bevacizumab
7%
Vasculotropin A
7%
Subretinal Neovascularization
6%
Subretinal Fluid
6%
Monotherapy
6%
Avacincaptad Pegol
6%
Carbonate Dehydratase IX
6%
Neovascularization (Pathology)
5%
Angiopoietin 2
5%
Triamcinolone Acetonide
5%
Biological Marker
5%
Keyphrases
Neovascular Age-related Macular Degeneration (nAMD)
43%
Diabetic Macular Edema
32%
Aflibercept
31%
Brolucizumab
24%
Best-corrected Visual Acuity
19%
Ranibizumab
19%
Visual Acuity
15%
Diabetic Retinopathy
14%
Anti-VEGF Therapy
13%
Subretinal Fluid
13%
Treat-and-extend
12%
Intravitreal Aflibercept
11%
Retinal Nonperfusion
11%
Intravitreal Aflibercept Injection
11%
Proliferative Diabetic Retinopathy
11%
Visual Acuity Outcome
10%
Confidence Interval
10%
Retinal Vein Occlusion
9%
IRIS Registry
9%
Ultra-high Field
9%
2-year Outcome
9%
Leakage Index
9%
Navigated Laser
9%
Faricimab
9%
Randomized Trial
9%
Age-related Macular Degeneration
8%
Central Subfield Thickness
8%
Intravitreal Injection
8%
ETDRS
8%
Pars Plana Vitrectomy
7%
Rhegmatogenous Retinal Detachment
6%
Intermediate Age-related Macular Degeneration
6%
Meta-analysis
6%
Anti-vascular Endothelial Growth Factor Therapy
6%
Visual Acuity Change
6%
Visual Outcome
6%
Ultra-widefield Fluorescein Angiography
6%
Diabetic Retinopathy Grading
6%
Retinal Vascular Bed Area
6%
Abicipar
6%
Xenon Arc
6%
Lighting Applications
6%
Macular Atrophy
6%
Residual Liquid
6%
Port Delivery System with Ranibizumab
6%
Randomized Clinical Trial
6%
Author Names
6%
Scleral Buckle
6%
Merlin
6%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
5%
